TrialSignal
Clinical trial intelligence report
A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07477431-Jul 28, 2026
NCT ID
NCT07477431
Status
RECRUITING
Phase
PHASE2
Sponsor
Sunnybrook Health Sciences Centre
Executive brief
Investment-Ready Snapshot
A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease is a PHASE2 clinical asset sponsored by Sunnybrook Health Sciences Centre in Hippocampal Hyperactivation, Prodromal Alzheimer Disease. SEO and diligence focus: Levetiracetam (LEV), Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07477431
Indication
Hippocampal Hyperactivation
Modality
small molecule
Target
Levetiracetam (LEV), Placebo
Intervention
Levetiracetam (LEV), Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.